SKIN - The Beauty Health Company Stock Price, Fair Value and News

3.16USD-0.06 (-1.86%)Delayed as of 24 Apr 2024, 03:00 pm ET

Market Summary

USD3.16-0.06

Delayedas of 24 Apr 2024, 03:00 pm

-1.86%

SKIN Alerts

JANUS HENDERSON GROUP PLC reported owning 10.6% of SKIN [2024-04-05]

SKIN Stock Price

View Fullscreen

SKIN RSI Chart

SKIN Valuation

Market Cap

397.4M

Price/Earnings (Trailing)

-3.97

Price/Sales (Trailing)

EV/EBITDA

-7.86

Price/Free Cashflow

22.17

SKIN Price/Sales (Trailing)

SKIN Profitability

Operating Margin

38.97%

EBT Margin

-25.86%

Return on Equity

-168.57%

Return on Assets

-10.78%

Free Cashflow Yield

4.51%

SKIN Fundamentals

SKIN Revenue

Revenue (TTM)

398.0M

Rev. Growth (Yr)

-1.34%

Rev. Growth (Qtr)

-0.61%

SKIN Earnings

Earnings (TTM)

-100.1M

Earnings Growth (Yr)

-243.93%

Earnings Growth (Qtr)

87.26%

Breaking Down SKIN Revenue

52 Week Range

3.1611.83

(Low)(High)

Last 7 days

-9.0%

Last 30 days

-24.9%

Last 90 days

14.6%

Trailing 12 Months

-74.4%

How does SKIN drawdown profile look like?

SKIN Financial Health

Current Ratio

6.07

Debt/Equity

12.43

Debt/Cashflow

0.03

SKIN Investor Care

Buy Backs (1Y)

8.33%

Diluted EPS (TTM)

-0.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	376.7M	390.7M	399.3M	398.0M
2022	288.0M	325.0M	345.6M	365.9M
2021	306.5M	358.9M	392.5M	260.1M
2020	0	150.8M	134.9M	119.1M
2019	0	0	0	166.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of The Beauty Health Company

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	monahan michael p.	acquired	-	-	292,207	chief financial officer
Apr 09, 2024	beck marla malcolm	acquired	-	-	837,662	president and ceo
Apr 09, 2024	watson daniel copell	acquired	-	-	243,506	chief revenue oficer
Nov 29, 2023	hauser bradley	acquired	-	-	176,711	chief operating officer
Nov 29, 2023	watson daniel copell	acquired	-	-	156,250	chief revenue oficer
Nov 29, 2023	monahan michael p.	acquired	-	-	176,711	chief financial officer
Nov 20, 2023	beck marla malcolm	acquired	-	-	213,675	interim ceo
Aug 17, 2023	miller brian christopher	bought	348,600	5.81	60,000	-
Aug 17, 2023	capellas michael d	bought	180,948	6.0316	30,000	-
Aug 17, 2023	stanleick andrew roy	bought	99,815	6.0549	16,485	chief executive officer

Which funds bought or sold SKIN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	unchanged	-	13,433	44,844	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-136,299	145,666	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	9.96	17,798	49,035	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-	-	-%
Apr 17, 2024	GRIMES & COMPANY, INC.	unchanged	-	292,282	975,739	0.03%
Apr 16, 2024	Pasadena Private Wealth, LLC	sold off	-100	-1,856,710	-	-%
Apr 16, 2024	TSFG, LLC	unchanged	-	-	-	-%
Apr 16, 2024	180 WEALTH ADVISORS, LLC	added	14.94	142,383	360,905	0.06%
Apr 05, 2024	CWM, LLC	added	912	5,000	5,000	-%
Apr 03, 2024	Versant Capital Management, Inc	new	-	1,239	1,239	-%

Are Funds Buying or Selling SKIN?

Are funds buying SKIN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SKIN

No. of Funds

SKIN Alerts

JANUS HENDERSON GROUP PLC reported owning 10.6% of SKIN [2024-04-05]

Unveiling The Beauty Health Company's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	janus henderson group plc	10.6%	13,238,594	SC 13G/A
Mar 14, 2024	lcp edge holdco llc	27.03%	33,360,741	SC 13D/A
Feb 14, 2024	luxor capital group, lp	1%	18,872	SC 13G/A
Feb 13, 2024	vanguard group inc	5.53%	7,258,870	SC 13G/A
Feb 13, 2024	janus henderson group plc	9.6%	12,716,793	SC 13G/A
Feb 09, 2024	senvest management, llc	0%	0	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Nov 09, 2023	janus henderson group plc	10.1%	13,531,260	SC 13G/A
Feb 14, 2022	luxor capital group, lp	1%	143,628	SC 13G/A

Recent SEC filings of The Beauty Health Company

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	PRE 14A	PRE 14A
Apr 09, 2024	8-K	Current Report
Apr 08, 2024	8-K	Current Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Mar 14, 2024	SC 13D/A	13D - Major Acquisition
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	8-K	Current Report

Peers (Alternatives to The Beauty Health Company)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
PG	381.1B	84.1B	-0.11%	3.28%	25.19	4.53	3.82%	5.63%
CL	72.9B	19.5B	-0.70%	13.74%	31.7	3.75	8.29%	28.85%
EL	53.4B	15.2B	4.01%	-41.28%	110.56	3.52	-7.33%	-68.01%
CHD	26.0B	5.9B	1.99%	16.13%	34.42	4.43	9.16%	82.56%
CLX	18.1B	7.3B	-3.18%	-11.03%	226.42	2.48	3.47%	-81.61%
COTY	10.5B	6.0B	-0.76%	-2.91%	32.32	1.74	14.07%	132.95%
ELF	9.8B	890.1M	-13.82%	86.82%	76.01	11.05	79.24%	176.22%
MID-CAP
IPAR	4.2B	1.3B	-5.54%	-16.25%	27.5	3.19	21.26%	26.23%
NWL	3.0B	8.1B	-6.79%	-40.80%	-7.61	0.36	-14.02%	-296.95%
HIMS	2.6B	872.0M	-24.43%	4.49%	-109.62	2.96	65.49%	64.15%
HELE	2.4B	2.0B	-10.88%	16.86%	14.7	1.19	-7.82%	10.32%
SMALL-CAP
EPC	1.9B	2.3B	0.24%	-14.32%	17.58	0.83	4.31%	6.67%
ACU	147.5M	191.5M	-6.98%	52.19%	8.29	0.77	-1.27%	486.29%
GROV	56.4M	259.3M	-6.36%	244.68%	-1.3	0.22	-19.36%	50.71%
UG	37.4M	10.9M	1.24%	-18.84%	14.49	3.44	-14.28%	0.46%

The Beauty Health Company News

Latest updates

The Beauty Health Company Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-0.6%	96,821,000	97,413,000	117,479,000	86,278,000	98,133,000	88,792,000	103,536,000	75,415,000	77,889,000	68,147,000	66,508,000	47,542,000	210,308,968	34,560,000	14,116,000	-
Cost Of Revenue	-53.5%	51,135,000	109,966,000	49,603,000	32,174,000	31,642,000	27,429,000	33,496,000	24,530,000	24,417,000	22,072,000	19,257,000	15,802,000	14,843,000	13,603,000	9,840,000	-
Gross Profit	463.9%	45,686,000	-12,553,000	67,876,000	54,104,000	66,491,000	61,363,000	70,040,000	50,885,000	53,472,000	46,075,000	47,251,000	31,740,000	23,037,000	20,957,000	4,276,000	-
Operating Expenses	-7.9%	64,046,000	69,548,000	81,022,000	71,414,000	68,939,000	65,716,000	75,067,000	64,898,000	63,973,000	51,531,000	73,604,000	29,358,000	27,748,000	18,172,000	12,195,000	-
S&GA Expenses	4.2%	32,025,000	30,731,000	43,041,000	38,699,000	39,021,000	39,767,000	44,881,000	36,407,000	37,438,000	30,451,000	26,214,000	17,095,000	15,898,500	10,541,000	6,186,000	-
R&D Expenses	65.6%	3,046,000	1,839,000	2,881,000	2,336,000	1,446,000	2,167,000	2,601,000	2,230,000	1,875,000	1,880,000	2,988,000	1,452,000	859,500	577,000	597,000	-
EBITDA Margin	-10.7%	-0.20	-0.18	0.00	0.01	0.17	0.12	-0.55	-1.13	-1.39	-0.90	-0.39	-0.05	-	-	-	-
Interest Expenses	-2.5%	3,358,000	3,445,000	3,429,000	3,417,000	3,395,000	3,380,000	3,217,000	3,400,000	1,528,000	-	7,126,000	3,123,000	3,104,000	3,171,000	3,111,000	-
Income Taxes	-82.7%	603,000	3,479,000	-2,193,000	-3,662,000	-780,500	-800,000	76,000	2,615,000	1,427,500	-1,100,000	-1,900,000	-300,000	-3,048,500	-593,000	-3,052,000	-
Earnings Before Taxes	88.9%	-7,787,000	-70,339,000	1,171,000	-25,947,000	5,778,000	-902,000	6,393,000	34,070,000	-19,537,000	-216,274,000	-141,248,000	-3,580,000	-10,542,000	-2,807,000	-13,449,000	-
EBT Margin	-15.2%	-0.26	-0.22	-0.05	-0.04	0.12	0.07	-0.59	-1.18	-1.45	-0.95	-0.44	-0.10	-	-	-	-
Net Income	87.3%	-9,403,000	-73,818,000	3,364,000	-20,259,000	6,533,000	-81,000	6,317,000	31,455,000	-20,967,000	-215,145,000	-139,378,000	-3,274,000	-7,494,000	-2,214,000	-10,397,000	-
Net Income Margin	-19.5%	-0.25	-0.21	-0.03	-0.02	0.12	0.06	-0.60	-1.18	-1.44	-0.93	-0.42	-0.08	-	-	-	-
Free Cashflow	-129.2%	-5,198,000	17,790,000	20,662,000	-15,329,000	-6,360,000	-35,704,000	-33,763,000	-41,620,000	-3,065,000	148,000	-37,088,000	443,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-4.5%	929	973	1,007	995	1,003	1,105	1,215	1,199	1,219	998	343	464	223	225	226
Current Assets	-5.4%	698	738	768	749	783	892	996	982	1,001	798	174	3.00	59.00	-	54.00
Cash Equivalents	-6.5%	523	559	550	532	568	684	821	859	902	719	101	14.00	9.00	12.00	7.00
Inventory	22.0%	91.00	75.00	107	122	110	102	74.00	47.00	35.00	28.00	24.00	22.00	23.00	-	19.00
Net PPE	-	-	-	-	-	-	-	-	-	-	12.00	10.00	8.00	9.00	-	11.00
Goodwill	0.9%	126	125	125	125	125	123	4.00	124	124	123	103	99.00	99.00	99.00	99.00
Liabilities	-1.5%	870	883	846	847	836	847	863	857	917	1,140	326	68.00	253	-	228
Current Liabilities	-8.6%	115	126	83.00	72.00	72.00	76.00	87.00	69.00	76.00	49.00	39.00	1.00	31.00	0.00	38.00
Long Term Debt	0.1%	738	737	736	735	734	733	732	731	730	729	-	218	-	-	181
LT Debt, Non Current	0.1%	738	737	736	735	734	733	732	731	730	729	-	218	-	-	181
Shareholder's Equity	-34.0%	59.00	90.00	162	152	167	251	345	336	298	-	16.00	-	5.00	0.00	-
Retained Earnings	-2.0%	-478	-469	-395	5.00	-378	-378	-378	-386	-418	-401	-186	-68.02	-43.60	0.00	-14.43
Additional Paid-In Capital	-4.1%	541	565	561	555	550	643	736	729	722	261	202	3.00	14.00	0.00	14.00
Shares Outstanding	-7.3%	123	133	133	133	132	151	151	151	102	132	64.00	36.00	-	-	-
Float	-	-	-	729	-	-	-	1,340	-	-	-	1,410	-	558	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Cashflow From Operations	-128.8%	-5,170	17,964	21,966	-13,010	-5,393	-31,401	-31,335	-38,471	3,279	298	-33,199	1,261	-752	-540*	-6,579	-5,054	-	-
Share Based Compensation	-72.4%	2,258	8,185	8,524	3,577	7,619	7,449	6,378	7,049	3,794	5,082	3,508	34.00	37.00	76.00	224	26.00	-	-
Cashflow From Investing	51.1%	-2,168	-4,436	-3,219	-21,684	-2,824	-7,741	-4,879	-3,425	-8,530	-20,082	-8,131	-988	-1,120	-1,272	818	-2,243	-	-
Cashflow From Financing	-1234.3%	-31,357	-2,350	-1,546	-2,195	-102,479	-100,000	-1,980	-783	188,210	637,776	128,672	4,377	231,707	26.00	14,480	6,057	-	-
Buy Backs	524.6%	30,155	4,828	-	-	80,000	80,000	-	-	-	-	-	-	-	-	-	-	-	-

SKIN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue from contract with customer	$ 397,991	$ 365,876	$ 260,086
Cost of sales	242,878	117,097	81,548
Gross profit	155,113	248,779	178,538
Operating expenses:
Selling and marketing	144,496	160,076	111,583
Research and development	10,102	8,444	8,195
General and administrative	131,432	106,100	98,688
Total operating expenses	286,030	274,620	218,466
Loss from operations	(130,917)	(25,841)	(39,928)
Interest expense	13,649	13,392	11,777
Interest income	(23,173)	(9,175)	(39)
Other (income) expense, net	(5,200)	1,650	4,489
Change in fair value of warrant liabilities	(11,919)	(78,343)	277,315
Change in fair value of earn-out shares	0	0	47,100
Foreign currency transaction (gain) loss, net	(2,385)	1,296	69
(Loss) income before provision for income taxes	(101,889)	45,339	(380,639)
Income tax (benefit) expense	(1,773)	1,115	(1,875)
Net (loss) income	(100,116)	44,224	(378,764)
Comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	1,494	(3,273)	(1,499)
Comprehensive (loss) income	$ (98,622)	$ 40,951	$ (380,263)
Net (loss) income per share
Basic (in dollars per share)	$ (0.76)	$ 0.30	$ (3.71)
Diluted (in dollars per share)	$ (0.76)	$ (0.23)	$ (3.71)
Weighted average common shares outstanding
Basic (in shares)	131,680,605	147,554,090	102,114,949
Diluted (in shares)	131,680,605	148,506,312	102,114,949

SKIN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 523,025	$ 568,197
Accounts receivable, net of allowances for estimated credit losses of $6,604 and $2,929 at December 31, 2023 and December 31, 2022, respectively	54,697	76,494
Prepaid expenses and other current assets	28,877	27,648
Income tax receivable	332	1,280
Inventories	91,321	109,656
Total current assets	698,252	783,275
Property and equipment, net	14,226	18,184
Right-of-use assets, net	12,120	15,637
Intangible assets, net	62,123	46,386
Goodwill	125,818	124,593
Deferred income tax assets, net	531	815
Other assets	16,043	14,193
TOTAL ASSETS	929,113	1,003,083
Current liabilities:
Accounts payable	44,768	28,467
Accrued payroll-related expenses	22,028	21,677
Syndeo Program reserves	21,009	0
Lease liabilities, current	4,598	4,958
Income tax payable	2,759	1,429
Other accrued expenses	19,846	15,183
Total current liabilities	115,008	71,714
Lease liabilities, non-current	9,319	12,689
Deferred income tax liabilities, net	702	2,011
Warrant liabilities	3,555	15,473
Convertible senior notes, net	738,372	734,143
Other long-term liabilities	2,767	0
Total liabilities	869,723	836,030
Commitments (Note 14)
Stockholders’ equity:
Class A Common Stock, $0.0001 par value; 320,000,000 shares authorized; 122,899,002 and 132,214,695 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	12	14
Additional paid-in capital	541,281	550,320
Accumulated other comprehensive loss	(3,036)	(4,530)
Accumulated deficit	(478,867)	(378,751)
Total stockholders’ equity	59,390	167,053
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 929,113	$ 1,003,083

About The Beauty Health Company

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.

CEO	Mr. Andrew Stanleick
WEBSITE	beautyhealth.com
INDUSTRY	Household Products
EMPLOYEES	1034

The Beauty Health Company Frequently Asked Questions

What is the ticker symbol for The Beauty Health Company? What does SKIN stand for in stocks?

SKIN is the stock ticker symbol of The Beauty Health Company. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of The Beauty Health Company (SKIN)?

As of Tue Apr 23 2024, market cap of The Beauty Health Company is 397.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SKIN stock?

You can check SKIN's fair value in chart for subscribers.

What is the fair value of SKIN stock?

You can check SKIN's fair value in chart for subscribers. The fair value of The Beauty Health Company is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of The Beauty Health Company is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SKIN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is The Beauty Health Company a good stock to buy?

The fair value guage provides a quick view whether SKIN is over valued or under valued. Whether The Beauty Health Company is cheap or expensive depends on the assumptions which impact The Beauty Health Company's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SKIN.

What is The Beauty Health Company's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, SKIN's PE ratio (Price to Earnings) is -3.97 and Price to Sales (PS) ratio is 1. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SKIN PE ratio will change depending on the future growth rate expectations of investors.